Group 1 - The core point of the article highlights the recent stock performance of JiaHua Co., which saw a decline of 2.06% on December 26, with a current share price of 16.16 yuan and a market capitalization of 2.659 billion yuan [1] - JiaHua Co. has experienced a year-to-date stock price increase of 45.45%, with a 1.25% rise over the last five trading days, a 0.37% increase over the last 20 days, and an 18.48% rise over the last 60 days [1] - The company, established on December 8, 2000, specializes in the research, production, and sales of soybean protein, with its main revenue sources being soybean protein (58.07%), soybean oil (21.94%), and dietary fiber (6.11%) [1] Group 2 - As of September 30, the number of shareholders for JiaHua Co. was 8,539, a decrease of 16.63% from the previous period, while the average circulating shares per person increased by 112.04% to 19,270 shares [1] - For the period from January to September 2025, JiaHua Co. reported a revenue of 1.027 billion yuan, a year-on-year decrease of 7.19%, while the net profit attributable to the parent company was 82.173 million yuan, reflecting a year-on-year increase of 7.46% [1] - The company has distributed a total of 181 million yuan in dividends since its A-share listing [2]

从资金流向上来看，当日农产品加工板块主力资金净流出1.25亿元，游资资金净流入960.72万元，散户资 金净流入1.16亿元。农产品加工板块个股资金流向见下表： 证券之星消息，12月25日农产品加工板块较上一交易日上涨0.07%，嘉华股份领涨。当日上证指数报收 于3959.62，上涨0.47%。深证成指报收于13531.41，上涨0.33%。农产品加工板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603182 | 嘉华股份 | 16.50 | 3.84% | 3.62万 | 5945.15万 | | 300175 | ST朗源 | 5.83 | 2.28% | 3.86万 | 2229.92万 | | 300268 | *ST佳沃 | 13.20 | 1.23% | 4 6446.0 | 848.59万 | | 000911 | 广农糖业 | 7.58 | 1.07% | 5.03万 | 3803.98万 | | 600737 | 中粮糖业 | 17.41 | 0.87% ...

Group 1 - The company Jia Hua Co., Ltd. reported that as of the end of the third quarter of 2025, the total number of shareholders is 8,539 [2]

山东嘉华生物科技股份有限公司 证券代码：603182 证券简称：嘉华股份 公告编号：2025-034 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 26 日 （星期三） 至 12 月 02 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 sinoglory@sinoglorygroup.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 山东嘉华生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 12 月 03 日（星期三） 10:00-11:00 举行 2025 年第三季度业绩说明会，就投资者关心的 ...

Core Viewpoint - The company has developed a comprehensive action plan for 2025 aimed at enhancing quality, efficiency, and returns, focusing on its core business of soybean protein and responding to regulatory initiatives to improve the quality of listed companies [1] Group 1: Business Strategy - The company aims to solidify its foundation for high-quality development by focusing on its core business of soybean protein, enhancing operational quality, and optimizing cost control [1][2] - The company is implementing a full-system collaboration model from raw material procurement to sales, ensuring coordinated operations across the supply chain [2] - The company plans to continue enhancing its professional advantages in the soybean protein sector and expand into the plant protein market through technological innovation and product upgrades [2][3] Group 2: Innovation and R&D - The company is committed to an innovation-driven development strategy, focusing on technological advancements and sustainable practices to enhance production efficiency [3][4] - The company has made breakthroughs in key technologies related to soybean protein and is actively collaborating with academic institutions to advance research and development [4] - A systematic intellectual property management system has been established to create technological barriers and enhance overall innovation capabilities [4] Group 3: Investor Relations - The company emphasizes the importance of investor relations management, ensuring timely and accurate information disclosure to protect investor rights [5][6] - Various communication channels have been established to facilitate interaction with investors, including investor meetings and dedicated consultation lines [5][6] - The company has organized investor performance briefings to discuss operational results and financial conditions, maintaining a high response rate to investor inquiries [5][6] Group 4: Corporate Governance - The company is enhancing its internal management controls and decision-making processes to protect the rights of minority shareholders [6][9] - A streamlined and efficient corporate governance structure has been established, ensuring compliance with relevant laws and regulations [6][9] - The company is focused on improving the capabilities of key personnel and enhancing compliance awareness through ongoing training [9] Group 5: Shareholder Returns - The company has a consistent cash dividend policy, having distributed a total of 181.005 million yuan in cash dividends since its listing, representing 41.70% of the total raised funds [7][8] - For the 2024 fiscal year, the company plans to distribute a cash dividend of 0.10 yuan per share, totaling 16.455 million yuan, which is 15.08% of the net profit attributable to shareholders [7][8] - The company aims to maintain a sustainable cash dividend mechanism while balancing operational needs and shareholder returns [8]

Core Viewpoint - The company has announced a comprehensive action plan for 2025 aimed at enhancing quality and efficiency while increasing returns to shareholders [1] Group 1: Strategic Focus - The company will concentrate on its core business to solidify the foundation for high-quality development [1] - Innovation will be a driving force for the development of new productive capacities [1] Group 2: Investor Relations - The company aims to enhance value transmission and deepen communication with investors [1] - There is a commitment to improving investor returns and sharing the results of operational development [1] Group 3: Governance and Accountability - The company plans to optimize its governance system and continuously improve corporate governance [1] - There will be an emphasis on enhancing the capabilities of key personnel and reinforcing accountability [1]

公司代码：603182 公司简称：嘉华股份 公告编号：2025-033 山东嘉华生物科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，贯 彻以投资者为本的发展理念，切实保障和维护投资者合法权益，推进山东嘉华生物 科技股份有限公司（以下简称"公司"）高质量发展和投资价值提升，公司结合实 际经营情况及发展战略，制定了《2025 年度"提质增效重回报"行动方案》（以下 简称"本行动方案"），具体内容如下： 一、聚焦主营业务，夯实高质量发展基础 2025 年，公司锚定"稳健经营、长远发展"战略方向，以大豆蛋白核心主业为 定位，聚焦主营业务深耕与综合实力提升，持续深化蛋白产品功能细分研究和应用 领域拓展，以产品服务为基，以客户市场为导，通过整合产品矩阵、提升服务质量、 优化成本管控、塑造品牌形象等多项举措，全面提升公司运营质效，推 ...

本次选举职工代表董事工作完成后，公司第六届董事会中兼任高级管理人员 职务的董事以及由职工代表担任的董事人数总计未超过公司董事总数的二分之 一，符合有关法律法规、规范性文件及《公司章程》的规定。 特此公告。 山东嘉华生物科技股份有限公司董事会 2025 年 11 月 20 日 证券代码：603182 证券简称：嘉华股份 公告编号：2025-032 山东嘉华生物科技股份有限公司 关于选举第六届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《中华人民共和国公司法》《山东嘉华生物科技股份有限公司章程》等 有关规定，山东嘉华生物科技股份有限公司（以下简称"公司"）董事会由九名 董事组成，其中含一名职工代表董事，由公司职工通过职工代表大会、职工大会 或者其他形式民主选举产生，无需提交股东会审议。 公司于 2025 年 11 月 18 日召开第四届职工代表大会第三次会议，经与会职 工代表审议，同意选举王才立先生为公司第六届董事会职工代表董事（简历详见 附件），任期自本次职工代表大会通过之日起至第六届董事会任期 ...

公司代码：603182 公司简称：嘉华股份 公告编号：2025-033 山东嘉华生物科技股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，积极响 应上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，贯 彻以投资者为本的发展理念，切实保障和维护投资者合法权益，推进山东嘉华生物 科技股份有限公司（以下简称"公司"）高质量发展和投资价值提升，公司结合实 际经营情况及发展战略，制定了《2025 年度"提质增效重回报"行动方案》（以下 简称"本行动方案"），具体内容如下： 一、聚焦主营业务，夯实高质量发展基础 2025 年，公司锚定"稳健经营、长远发展"战略方向，以大豆蛋白核心主业为 定位，聚焦主营业务深耕与综合实力提升，持续深化蛋白产品功能细分研究和应用 领域拓展，以产品服务为基，以客户市场为导，通过整合产品矩阵、提升服务质量、 优化成本管控、塑造品牌形象等多项举措，全面提升公司运营质效，推 ...

Core Insights - The plant protein industry, particularly soybean protein, is experiencing rapid growth due to increasing awareness of health and nutrition, with the market size in China projected to reach 16.161 billion yuan in 2024, a year-on-year increase of 4.47% [1][10]. Overview - Protein is essential for life and is composed of amino acids, with 20 types in total. Among these, 8 are essential and must be obtained from food. Plant proteins, particularly from beans, are lower in cholesterol and saturated fats, making them suitable for individuals with liver diseases and for preventing cardiovascular diseases [2][4]. Industry Barriers - The soybean protein industry is subject to strict regulations and quality control measures, including licensing and traceability requirements. New entrants face high technical barriers due to the established production processes and technology of existing players [6][7]. Market Policies - The Chinese government has implemented various policies to enhance soybean self-sufficiency and ensure quality control in soybean protein production. These policies promote the development of the soybean industry and require strict adherence to safety and quality standards [8]. Industry Chain - The soybean protein industry encompasses upstream activities such as soybean cultivation and procurement, midstream production, and downstream applications in various sectors including meat processing, snacks, dairy, and pharmaceuticals. The cost structure indicates that direct materials account for over 60% of production costs, with soybean being the primary raw material [8][9]. Current Development - Soybean is recognized for its high protein content and nutritional value, with various health benefits including cholesterol reduction and improved gut health. The domestic market for soybean protein is maturing rapidly, with significant growth in applications across multiple sectors [10][11]. Competitive Landscape - The soybean protein industry in China has seen the emergence of several key players, including Shandong Yuwang Ecological Food Co., Ltd., and Ningbo Suobao Protein Technology Co., Ltd. These companies are expanding their product offerings and market presence [11][12]. Future Trends - The soybean protein industry is shifting towards high-end products, with increasing production of high-purity and organized proteins. Innovations in processing technologies are expected to enhance the application of soybean protein in emerging fields such as pharmaceuticals and 3D printing [14][15].